Qiagen stock remains steady as investors await fresh numbers
Published on 08/09/2026 at 14:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Qiagen stock remains the focus for investors after the latest published financial context showed revenue of €2.05 billion for 2025, a gross margin of 69.5%, and diluted EPS of €1.51. The company is Qiagen N.V. (ISIN NL0012169213), and its investor relations page provides the current reporting framework for the shares.
2025 revenue and margin
For 2025, Qiagen reported revenue of €2.05 billion, up from €1.99 billion in 2024. Gross margin reached 69.5% in 2025, while diluted EPS improved to €1.51 from €1.43 the year before.
That combination gives the stock a clear earnings base even without a fresh market-triggered headline in the available material. The year-over-year revenue increase of €60 million is a useful reference point for how the business is still expanding.
Cash flow stayed positive
Qiagen also reported free cash flow of $384 million in 2025, compared with $339 million in 2024. Net debt stood at $1.35 billion at the end of 2025, which keeps balance-sheet leverage an important part of the equity story.
For investors, the most relevant comparison is not only profit growth but also cash generation. The free cash flow increase of $45 million year on year shows the company converting earnings into liquidity.
Investor relations anchor
The company’s investor relations page is the natural reference point for the latest report cycle and future updates. Qiagen has used that channel to present its annual and quarterly results, including the 2025 figures that frame the current stock discussion.
Revenue, margin, and cash flow matter more than broad business descriptions here. The reported 2025 gross margin of 69.5% and diluted EPS of €1.51 give investors a concise way to compare the business with prior periods.
Product line and demand
Qiagen’s core portfolio centers on sample and assay technologies used in molecular testing and life-science workflows. That product mix is important because recurring consumables and testing platforms typically shape how revenue quality is read in the market.
The 2025 numbers suggest that the commercial base is still large enough to support this model, with €2.05 billion in annual revenue and positive free cash flow in the same year.
Stock and valuation context
Qiagen stock can be assessed against the 2025 operating backdrop rather than a one-day trading move. With no dated market quote in the available material, the more durable market anchors are the €2.05 billion revenue base, 69.5% gross margin, and $384 million free cash flow.
Qiagen at a glance
- Company: Qiagen N.V.
- ISIN: NL0012169213
- Ticker: NYSE: QGEN
- Trading venue: New York Stock Exchange
- Sector / Industry: Health Care / Life Sciences Tools and Services
- Index membership: N/A
- Next earnings date: N/A
